Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Off the shelf T-cells therapy for viral infection post HCST
Sponsor:Pediatric Bone Marrow Transplant Consortium
Enrolling:Male and Female Patients
Study Length:3 Years
IRB Number:AAAR8071
Contact: Jean Sosna, RN: 212-305-2050 / js4403@cumc.columbia.edu
Additional Study Information:

In this trial, we will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy. This will be in patients who have received a hematopoietic stem cell transplant or patients with primary immunodeficiency conditions who have persistent viral infections and have not undergone HSCT.

This study is closed
Investigator
Prakash Satwani, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Jean Sosna, RN
Email: js4403@cumc.columbia.edu
Phone: 212-305-2050